Sign in
Active, not recruitingNo phase

EUS Elastography for Predicting Cirrhotic-related Complications

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
50 people, planned
Started
4 Nov 2019
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • EUS elastography
Record updated
19 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening
  • Patients with suspected advanced liver fibrosis as detected by Fibroscan
  • Patients with clinical evidence of hypersplenism
  • Age > 18 years
  • Written informed consent available

Who cannot take part

  • Patients with features of decompensated cirrhosis, such as history of ascites, prior variceal bleeding, hepatic encephalopathy, hepatorenal syndrome
  • Patients with history of hepatocellular carcinoma
  • Patients with history of liver transplant or TIPS or shunting surgery
  • Patients with portal and/or mesenteric vein thrombosis
  • Moribund patients from terminal illnesses
  • Patients with terminal malignancy
  • Contraindications for endoscopy
  • Unable to provide written informed consent
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluation of the tissue stiffness as a surrogate marker of degree of liver cirrhosis has gained popularity in recent decades. Current guidelines also advocate the use of Fibroscan® machine (EchoSens, Paris, France) to detect any advanced liver fibrosis as represented by high liver stiffness, for prediction of varices development.

Read full original descriptionShow less

Apart from liver stiffness, studies have shown that spleen stiffness (SS) has been proven another useful parameter to severity of underlying portal hypertension and liver cirrhosis. However, spleen stiffness measurement by Fibroscan® is highly limited by the thickness of subcutaneous soft tissue or abdominal wall tissue, especially in obese subjects. It carries certain technical difficulty as well due to its deep-seated anatomical position.

Recently, the technique of endoscopic ultrasound elastography (EUS-E) has been described. It can overcome the limitations of Fibroscan by making measurements of liver and spleen stiffness through the gastric wall, which has a shorter distance than the abdominal wall. It also allows concomitant upper GI tract luminal examination, incorporating both esophagogastroduodenoscopy and elastography measurements into one procedure at the same time. This research study aims to prospectively study the utility of EUS-E in patients with chronic liver diseases, both in terms of diagnostic and prognostic indications for future cirrhotic-related complications.

The group in the trial

  • Study group

    Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study

    Treatment: EUS elastography

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Study on the Utility of Endoscopic Ultrasound Elastography (EUS-E) for Predicting Cirrhotic-related Complications in Patients With Chronic Liver Diseases
Record updated
19 March 2026